Literature DB >> 29198014

Inhibition of Complement Drives Increase in Early Growth Response Proteins and Neuroprotection Mediated by Salidroside After Cerebral Ischemia.

Wenfang Lai1, XiuLi Xie1, Xiaoqin Zhang1, Yingzheng Wang1, Kedan Chu1, John Brown1, Lidian Chen1, Guizhu Hong2.   

Abstract

Salidroside is neuroprotective across a wide therapeutic time-window after cerebral ischemia-reperfusion injury (IRI). Here, we investigated the role of complement in mediating effects of salidroside after cerebral IRI in rats. Rats were administrated with vehicle or salidroside 50 mg/kg, given daily for either 24 or 48 h, after middle cerebral artery occlusion (MCAO) for 2 h and reperfusion for 1 h. Levels of proteins in ischemic brain were measured by immunofluorescence and western blotting. We observed early increases in the deposition of immunoglobulin M, mannose-binding lectin 2, and annexin IV on cerebral endothelial cells, induction of the complement components C3 and C3a, by 24 h after IRI, and a later significant increase in the complement component C1q by 48 h. Salidroside prevented these changes. The neuroplasticity-related early growth response proteins Egr1, Egr2, and Egr4 and activity-regulated cytoskeleton-associated protein increased transiently in the first 6 h after IRI but then decreased below baseline by 48 h after IRI. Neither salidroside nor a C3a receptor antagonist (C3aRA) affected these proteins 24 h after IRI, but both reversed their later decreases to similar and non-additive extents. Salidroside and C3aRA increased NeuN in a non-additive manner after IRI. Our results suggest that salidroside exerts neuroprotection by reducing early activation of the lectin pathway on the cerebral endothelium and inhibiting the gradual activation of the classical pathway after cerebral IRI. This prolonged neuroprotection may depend, at least in part, on increased expression of neuroplasticity-related genes driven by reduced complement activation.

Entities:  

Keywords:  Brain ischemia; Complement; Neuroprotection; Salidroside

Mesh:

Substances:

Year:  2018        PMID: 29198014     DOI: 10.1007/s10753-017-0701-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  48 in total

1.  Complement-dependent P-selectin expression and injury following ischemic stroke.

Authors:  Carl Atkinson; Hong Zhu; Fei Qiao; Juan Carlos Varela; Jin Yu; Hongbin Song; Mark S Kindy; Stephen Tomlinson
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

2.  The alternative complement pathway propagates inflammation and injury in murine ischemic stroke.

Authors:  Andrew Elvington; Carl Atkinson; Hong Zhu; Jin Yu; Kazue Takahashi; Gregory L Stahl; Mark S Kindy; Stephen Tomlinson
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

3.  Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model.

Authors:  L Belayev; O F Alonso; R Busto; W Zhao; M D Ginsberg
Journal:  Stroke       Date:  1996-09       Impact factor: 7.914

4.  Mannose-binding lectin promotes local microvascular thrombosis after transient brain ischemia in mice.

Authors:  Xavier de la Rosa; Alvaro Cervera; Anna K Kristoffersen; Claudia P Valdés; Hari M Varma; Carles Justicia; Turgut Durduran; Ángel Chamorro; Anna M Planas
Journal:  Stroke       Date:  2014-03-27       Impact factor: 7.914

5.  11β-HSD1 modulates LPS-induced innate immune responses in adipocytes by altering expression of PTEN.

Authors:  Wenfang Lai; Xue Tian; Qing Xiang; Kedan Chu; Yicong Wei; Jingti Deng; Shaoping Zhang; John Brown; Guizhu Hong
Journal:  Mol Endocrinol       Date:  2015-03-03

6.  Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke.

Authors:  Alvaro Cervera; Anna M Planas; Carles Justicia; Xabier Urra; Jens C Jensenius; Ferran Torres; Francisco Lozano; Angel Chamorro
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

7.  Genome-wide gene expression analysis for induced ischemic tolerance and delayed neuronal death following transient global ischemia in rats.

Authors:  Nobutaka Kawahara; Yan Wang; Akitake Mukasa; Kazuhide Furuya; Tatsuya Shimizu; Takao Hamakubo; Hiroyuki Aburatani; Tatsuhiko Kodama; Takaaki Kirino
Journal:  J Cereb Blood Flow Metab       Date:  2004-02       Impact factor: 6.200

8.  Salidroside protects against hydrogen peroxide-induced injury in HUVECs via the regulation of REDD1 and mTOR activation.

Authors:  Mao-Chun Xu; Hai-Ming Shi; Hao Wang; Xiu-Fang Gao
Journal:  Mol Med Rep       Date:  2013-05-09       Impact factor: 2.952

9.  Independent cellular processes for hippocampal memory consolidation and reconsolidation.

Authors:  Jonathan L C Lee; Barry J Everitt; Kerrie L Thomas
Journal:  Science       Date:  2004-04-08       Impact factor: 47.728

10.  C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury.

Authors:  Sean M Silverman; Byung-Jin Kim; Garreth R Howell; Joselyn Miller; Simon W M John; Robert J Wordinger; Abbot F Clark
Journal:  Mol Neurodegener       Date:  2016-03-24       Impact factor: 14.195

View more
  11 in total

1.  Salidroside Reduces Inflammation and Brain Injury After Permanent Middle Cerebral Artery Occlusion in Rats by Regulating PI3K/PKB/Nrf2/NFκB Signaling Rather than Complement C3 Activity.

Authors:  X Zhang; W Lai; X Ying; L Xu; K Chu; J Brown; L Chen; G Hong
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

2.  Salidroside Restores an Anti-inflammatory Endothelial Phenotype by Selectively Inhibiting Endothelial Complement After Oxidative Stress.

Authors:  Y Wang; Y Su; W Lai; X Huang; K Chu; J Brown; G Hong
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

3.  Salidroside Inhibits Reactive Astrogliosis and Glial Scar Formation in Late Cerebral Ischemia via the Akt/GSK-3β Pathway.

Authors:  Chengya Dong; Shaohong Wen; Shunying Zhao; Si Sun; Shangfeng Zhao; Wen Dong; Pingxin Han; Qingfang Chen; Ting Gong; Wentao Chen; Wenqian Liu; Xiangrong Liu
Journal:  Neurochem Res       Date:  2021-01-03       Impact factor: 3.996

Review 4.  Neuroprotective Phytochemicals in Experimental Ischemic Stroke: Mechanisms and Potential Clinical Applications.

Authors:  Hui Xu; Emily Wang; Feng Chen; Jianbo Xiao; Mingfu Wang
Journal:  Oxid Med Cell Longev       Date:  2021-04-28       Impact factor: 6.543

Review 5.  Pharmacological activities, mechanisms of action, and safety of salidroside in the central nervous system.

Authors:  Zhifeng Zhong; Jing Han; Jizhou Zhang; Qing Xiao; Juan Hu; Lidian Chen
Journal:  Drug Des Devel Ther       Date:  2018-05-24       Impact factor: 4.162

6.  Traumatic brain injury induces long-lasting changes in immune and regenerative signaling.

Authors:  Deborah R Boone; Harris A Weisz; Hannah E Willey; Karen E O Torres; Michael T Falduto; Mala Sinha; Heidi Spratt; Ian J Bolding; Kathea M Johnson; Margaret A Parsley; Douglas S DeWitt; Donald S Prough; Helen L Hellmich
Journal:  PLoS One       Date:  2019-04-03       Impact factor: 3.240

7.  Neuroprotective Effects of Salidroside on Cerebral Ischemia/Reperfusion-Induced Behavioral Impairment Involves the Dopaminergic System.

Authors:  Zhi-Feng Zhong; Jing Han; Ji-Zhou Zhang; Qing Xiao; Jing-Yan Chen; Kai Zhang; Juan Hu; Li-Dian Chen
Journal:  Front Pharmacol       Date:  2019-12-13       Impact factor: 5.810

Review 8.  Emerging recognition of the complement system in hepatic ischemia/reperfusion injury, liver regeneration and recovery (Review).

Authors:  Zhi-Gao Hu; Yi Zhou; Cheng-Jie Lin; Guan-Dou Yuan; Song-Qing He
Journal:  Exp Ther Med       Date:  2021-01-18       Impact factor: 2.447

Review 9.  Neuronal Loss after Stroke Due to Microglial Phagocytosis of Stressed Neurons.

Authors:  Guy C Brown
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

10.  Salidroside inhibits endothelial‑mesenchymal transition via the KLF4/eNOS signaling pathway.

Authors:  Yongpan Huang; Xiaodong Han; Jiayu Tang; Xian Long; Xiaoye Wang
Journal:  Mol Med Rep       Date:  2021-08-09       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.